Sete Lagoas

Researchers are evaluating the effects of inspiratory muscle training (IMT) on athletes participating in CrossFit® activities. This randomized controlled trial aims to assess how IMT influences respiratory muscle strength and perceived fatigue after training. Ninety-four volunteers aged 18 to 60 years who are enrolled in CrossFit® programs will take part in this study to better understand the potential benefits of IMT in this athletic population. Participants will be randomly assigned to one of two groups: the IMT group or the Non-IMT group. The IMT group will perform respiratory training using a POWERbreathe® device set at 50% of their maximum inspiratory pressure (MIP), completing two sets of 30 breaths with a one-minute rest in between, alongside their regular CrossFit® training. The Non-IMT group will follow the same CrossFit® training routine but will use a device without resistance for simulated respiratory training. CrossFit® sessions include warm-up, strength training, aerobic and anaerobic exercises, and mobility work, with participants encouraged to attend at least five sessions per week. Throughout the study, researchers will collect data on respiratory muscle strength (measuring maximum inspiratory and expiratory pressures), performance in various CrossFit® exercises, the six-minute walk test, and perceived fatigue. Assessments will take place at the start, mid-term (8 weeks), and long-term (12 weeks) after group allocation. Data such as age, body measurements, heart rate, blood pressure, smoking history, and medication use will also be recorded. The study will use statistical models to analyze the effects of IMT on respiratory strength and physical performance over time.

Researchers are evaluating several repurposed therapies including Fluvoxamine plus Budesonide, Fluoxetine plus Budesonide, and Spirulin Platensis to treat patients with early-onset COVID-19 who have mild symptoms but are at high risk for complications. This phase 3, double-blind, randomized, placebo-controlled study aims to assess if these treatments can reduce emergency care visits, hospitalizations, and oxygen desaturation events related to COVID-19 progression. The study builds on observational and experimental evidence suggesting these agents may have anti-inflammatory effects beneficial in early SARS-CoV-2 infection. Participants receive one of the study treatments or placebo following specific dosing schedules: Spirulin Platensis is given as two tablets every 12 hours for 10 days; Fluvoxamine plus Budesonide involves Fluvoxamine tablets every 12 hours and Budesonide inhalation every 12 hours for 10 days; Fluoxetine plus Budesonide is administered as Fluoxetine tablets daily plus Budesonide inhalation every 12 hours for 7 days. Placebo groups receive matching oral and inhalation placebos or paracetamol as an active comparator. The study includes adaptive modifications such as the addition of new treatment arms and changes to primary endpoints. During the 28-day follow-up, participants are monitored for emergency visits due to worsening COVID-19, hospitalizations related to disease progression, and oxygen saturation levels. Researchers evaluate safety and treatment effects through clinical assessments, laboratory tests, and symptom tracking. Participants must consent to treatment and follow study procedures, with ongoing monitoring for adverse events and protocol adherence throughout the study period.